文献速递淋巴瘤

一线Polatuzumab-R-CHP和/或二线CD19 CAR-T对比标准方案治疗中高危弥漫大B细胞淋巴瘤的成本效果分析

Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2022-10-31

研究构建Markov模型,比较四种策略治疗新诊断中高危弥漫大B细胞淋巴瘤的成本效果,包括一线polatuzumab-R-CHP联合或不联合二线CAR-T、标准方案联合或不联合二线CAR-T。从美国和加拿大支付方角度计算,ICER值均远高于15万美元或加元/QALY的支付意愿阈值,结论认为在当前定价下上述策略均不大可能具有成本效果。

要点

  • 一线polatuzumab-R-CHP联合二线CAR-T的ICER为546,956美元/QALY和245,381加元/QALY。
  • 标准方案联合二线CAR-T的ICER为309,813美元/QALY和303,163加元/QALY。
  • 同时联合polatuzumab-R-CHP与二线CAR-T的ICER为488,284美元/QALY和267,050加元/QALY。

核心结论

  • 鉴于长期生存的增量获益不确定且成本高昂,一线polatuzumab-R-CHP、二线CAR-T或两者联合在美国或加拿大当前定价下对比标准方案均不大可能具有成本效果。

研究设计与样本

  • 构建Markov模型,比较四种策略用于新诊断中高危弥漫大B细胞淋巴瘤患者。
  • 策略1:polatuzumab-R-CHP联合二线CAR-T用于早期复发(<12个月)。
  • 策略2:polatuzumab-R-CHP联合二线挽救治疗±自体干细胞移植。
  • 策略3:R-CHOP联合二线CAR-T用于早期复发。
  • 策略4:标准方案(R-CHOP联合二线挽救治疗±自体干细胞移植)。

主要发现

  • 概率分析(10,000次模拟)中,每种策略较前一策略增量更有效但成本也更高。
  • 标准方案基础上加用polatuzumab-R-CHP的ICER为546,956(338,797-1,199,923)美元/QALY和245,381(151,671-573,250)加元/QALY。
  • 标准方案基础上加用二线CAR-T的ICER为309,813(190,197-694,200)美元/QALY和303,163(221,300-1,063,864)加元/QALY。
  • 标准方案基础上同时加用polatuzumab-R-CHP和二线CAR-T的ICER为488,284(326,765-840,157)美元/QALY和267,050(182,832-520,922)加元/QALY。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent studies of polatuzumab vedotin and CD19 chimeric antigen receptor T-cell therapy (CAR-T) have shown significant improvements in progression-free survival over standard of care (SOC) for patients with diffuse large B-cell lymphoma. However, they are costly, and it is unclear whether these strategies, alone or combined, are cost-effective over SOC. METHODS: A Markov model was constructed to compare four strategies for patients with newly diagnosed intermediate- to high-risk diffuse large B-cell lymphoma: strategy 1: polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) plus second-line CAR-T for early relapse (< 12 months); strategy 2: polatuzumab-R-CHP plus second-line salvage therapy ± autologous stem-cell transplant; strategy 3: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus second-line CAR-T for early relapse; strategy 4: SOC (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus second-line salvage therapy ± autologous stem-cell transplant). Transition probabilities were estimated from trial data. Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated from US and Canadian payer perspectives. Willingness-to-pay (WTP) thresholds of $150,000 US dollars (USD) or Canadian dollars (CAD)/QALY were used. RESULTS: In probabilistic analyses (10,000 simulations), each strategy was incrementally more effective than the previous strategy, but also more costly. Adding polatuzumab-R-CHP to the SOC had an ICER of $546,956 (338,797-1,199,923) USD/QALY and $245,381 (151,671-573,250) CAD/QALY. Adding second-line CAR-T to the SOC had an ICER of $309,813 (190,197-694,200) USD/QALY and $303,163 (221,300-1,063,864) CAD/QALY. Simultaneously adding both polatuzumab-R-CHP and second-line CAR-T to the SOC had an ICER of $488,284 (326,765-840,157) USD/QALY and $267,050 (182,832-520,922) CAD/QALY. CONCLUSION: Given uncertain incremental benefits in long-term survival and high costs, neither polatuzumab-R-CHP frontline, CAR-T second-line, nor a combination are likely to be cost-effective in the United States or Canada at current pricing compared with the SOC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vijenthira A, Kuruvilla J, Crump M, et al. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2022. PMID: 36315922. doi:10.1200/JCO.22.00478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。